Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 107

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Encephalitis autoimmune

Recruiting

Study on Bortezomib for Patients with Severe Autoimmune Encephalitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Soft tissue sarcoma

Recruiting

Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Soft Tissue Sarcoma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine Citrate
  • Sponsor:Oncopole Claudius Regaud

Haematological malignancy+1

Recruiting

Study on Enhanced GVH Prevention in Elderly Patients with Blood Cancer Using Rabbit Anti-Human Thymocyte Immunoglobulin During Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rabbit Anti-Human Thymocyte Immunoglobulin
  • Sponsor:Institut Paoli-Calmettes

Neoplasm malignant

Recruiting

Study of durvalumab alone and in combination with tremelimumab in children with advanced solid tumors and blood cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Recruiting

Study on Self-Administration of Elranatamab for Patients with Multiple Myeloma at Home

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Odense University Hospital

Haematological malignancy+1

Recruiting

Study on the Safety of CA-4948 and Ibrutinib for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Malignant melanoma

Recruiting

Study on Reducing Bleomycin Dose in Electrochemotherapy for Patients with Skin Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Region Sjaelland

Chondrosarcoma+1

Recruiting

Study on Trabectedin for Adults and Young Adults with Advanced Mesenchymal Chondrosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Trabectedin
  • Sponsor:Italian Sarcoma Group

Plasma cell myeloma

Recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Colorectal cancer metastatic+2

Recruiting

Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasm malignant

Recruiting

Study on 68Ga-FAPI-46 for Imaging Pancreatic, Stomach, Bile Duct, and Ovarian Cancers in Patients with Solid Tumors

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Karolinska University Hospital

Breast cancer

Recruiting

Study on 18F-FES PET/MRI for Patients with Luminal A and Lobular Breast Cancer to Improve Treatment Decisions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Universita' Vita-salute S. Raffaele

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.